Beximco Pharmaceuticals (LSE:BXP) Moat Score: 0/10 (As of Jul. 08, 2026)


LSE:BXP Beximco Pharmaceuticals PLC LSE:BXP
68 GF Score
Price £0.50
GF Value £0.49
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Moat Score?

Beximco Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Beximco Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Beximco Pharmaceuticals might have No Moat - No discernible moat.

Beximco Pharmaceuticals  (LSE:BXP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Beximco Pharmaceuticals Moat Score Related Terms

LSE:BXP
68GF Score
Beximco Pharmaceuticals PLC LSE:BXP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of £0.50 is trading 2% above its estimated GF Value™ of £0.49. GuruFocus considers Beximco Pharmaceuticals to be Fairly Valued.

Key valuation signals for LSE:BXP:

  • Moat Score: 0
  • GF Value™: £0.49 vs. price of £0.50 (2% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
68GF Score

Get the complete analysis for LSE:BXP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.50
Price
£0.49
GF Value